While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

A higher prostate cancer behavior score was associated with a 31% reduction in the hazard for all-cause mortality and a 33% ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Records show that drug companies gave nearly $75,000 to the top Republican and Democrat on a committee investigating them.

Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...